{"fetched":"2026-09-17","feeds":[{"id":"fda-oce","name":"FDA Oncology Center of Excellence","homepage":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","kind":"regulator","sourceId":"fda-approvals","ok":true,"count":8},{"id":"nejm","name":"New England Journal of Medicine","homepage":"https://www.nejm.org/","url":"https://www.nejm.org/action/showFeed?type=etoc&feed=rss&jc=nejm","kind":"journal","sourceId":"nejm","onlyOncology":true,"ok":false,"count":3,"error":"unreachable or blocked; showing 3 items from 2026-09-10"},{"id":"lancet-oncology","name":"The Lancet Oncology","homepage":"https://www.thelancet.com/journals/lanonc/home","url":"https://www.thelancet.com/rssfeed/lanonc_current.xml","kind":"journal","sourceId":"lancet-oncology","ok":false,"count":28,"error":"unreachable or blocked; showing 28 items from 2026-09-10"},{"id":"jco","name":"Journal of Clinical Oncology","homepage":"https://ascopubs.org/journal/jco","url":"https://ascopubs.org/action/showFeed?type=etoc&feed=rss&jc=jco","kind":"journal","sourceId":"jco","ok":true,"count":40},{"id":"nature-medicine","name":"Nature Medicine","homepage":"https://www.nature.com/nm/","url":"https://www.nature.com/nm.rss","kind":"journal","sourceId":"nature-medicine","onlyOncology":true,"ok":true,"count":2},{"id":"endpoints","name":"Endpoints News","homepage":"https://endpts.com/","url":"https://endpts.com/feed/","kind":"news","sourceId":"src-endpoints-news","onlyOncology":true,"ok":true,"count":4},{"id":"stat","name":"STAT","homepage":"https://www.statnews.com/","url":"https://www.statnews.com/feed/","kind":"news","sourceId":"src-stat-news","onlyOncology":true,"ok":true,"count":2}],"items":[{"feedId":"endpoints","title":"Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease","url":"https://endpoints.news/sling-gets-123m-for-phase-3-trial-of-ex-astellas-drug-in-thyroid-eye-disease/","date":"2026-09-16","refs":["astellas","adienne"]},{"feedId":"stat","title":"Opinion: How my cancer diagnosis changed the way I train physicians","url":"https://www.statnews.com/2026/09/16/medical-school-cancer-structure-pathology-professor-personal-experience/?utm_campaign=rss","date":"2026-09-16","refs":["pathology-foundation-model"]},{"feedId":"jco","title":"Recent Population-Level Trends in Utilization of Outpatient Medical Oncology Services","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01156","date":"2026-09-15","refs":[]},{"feedId":"jco","title":"Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00285","date":"2026-09-15","refs":["ewing-sarcoma"]},{"feedId":"nature-medicine","title":"Beyond the breakthrough for RAS-driven cancers","url":"https://www.nature.com/articles/s41591-026-04610-4","date":"2026-09-15","refs":[]},{"feedId":"nature-medicine","title":"Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS G12D mutations: a phase 1 trial","url":"https://www.nature.com/articles/s41591-026-04559-4","date":"2026-09-15","refs":["nct07491497","nct05180799","nct06480565","nct05585320","nct06427941","nct06956690","nct04988555","nct07020221"]},{"feedId":"endpoints","title":"FDA approves first radioligand generic, setting up rivalry with Novartis","url":"https://endpoints.news/fda-approves-first-radioligand-generic-setting-up-rivalry-with-novartis/","date":"2026-09-15","refs":["lutathera","novartis","leucovorin","curium"]},{"feedId":"endpoints","title":"GSK strikes deal for Chimagen’s T cell engager for blood cancer","url":"https://endpoints.news/gsk-strikes-deal-for-chimagens-t-cell-engager-for-blood-cancer/","date":"2026-09-15","refs":["leukaemia"]},{"feedId":"stat","title":"STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more","url":"https://www.statnews.com/pharmalot/2026/09/15/gsk-china-drug-licensing-deal-job-losses/?utm_campaign=rss","date":"2026-09-15","refs":["multiple-myeloma"]},{"feedId":"jco","title":"Bridging the Gap: Precision Oncology for Cancers of Unknown Primary","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01847","date":"2026-09-14","refs":[]},{"feedId":"endpoints","title":"BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer","url":"https://endpoints.news/biontech-says-ctla-4-drug-nearly-doubled-survival-times-for-lung-cancer/","date":"2026-09-14","refs":["gotistobart","lung-cancer","biontech","ctla4"]},{"feedId":"jco","title":"Acknowledgment of Reviewers 2026","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01815","date":"2026-09-11","refs":[]},{"feedId":"jco","title":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00602","date":"2026-09-11","refs":["trastuzumab-emtansine","breast-cancer","trastuzumab","nct06891833","nct06590246"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small","date":"2026-09-09","refs":["nct05318573","sevabertinib","lung-cancer","nct06590246","bayer","her2","beone"]},{"feedId":"jco","title":"Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00769","date":"2026-09-09","refs":["pembrolizumab","nct05224141","sarcoma"]},{"feedId":"jco","title":"LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00451","date":"2026-09-09","refs":["dlbcl","nct05487170","non-hodgkin-lymphoma","nct07075328"]},{"feedId":"jco","title":"Purple Blossoms","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00469","date":"2026-09-08","refs":[]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative","date":"2026-09-04","refs":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","estrogen-receptor"]},{"feedId":"jco","title":"Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02974","date":"2026-09-03","refs":["cancer-of-unknown-primary","nct05744687","nct05281471","nct06463665","nct07290088"]},{"feedId":"jco","title":"Bridging the Gap: Mounting Evidence for Metastasis-Directed Therapy in Oligometastatic Disease","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01339","date":"2026-09-02","refs":[]},{"feedId":"nejm","title":"Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2504059?af=R&rss=currentIssue","date":"2026-09-02","refs":["nsclc","sclc","daraxonrasib"]},{"feedId":"nejm","title":"Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2602804?af=R&rss=currentIssue","date":"2026-09-02","refs":["azacitidine","venetoclax"]},{"feedId":"nejm","title":"Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML","url":"https://www.nejm.org/doi/full/10.1056/NEJMe2607967?af=R&rss=currentIssue","date":"2026-09-02","refs":["venetoclax"]},{"feedId":"jco","title":"Bridging the Gap: Clinical Integration of Thrombopoietin Receptor Agonists in GI Cancer–Associated Chemotherapy-Induced Thrombocytopenia","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01447","date":"2026-09-01","refs":[]},{"feedId":"lancet-oncology","title":"[Editorial] Beyond cancer: The Right to be Forgotten","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00399-2/fulltext","date":"2026-09-01","refs":[]},{"feedId":"lancet-oncology","title":"[Comment] Radiotherapy dose intensification for high-risk prostate cancer—what is gained?","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00346-3/fulltext","date":"2026-09-01","refs":["androgen-deprivation","prostate"]},{"feedId":"lancet-oncology","title":"[Comment] Beyond visual tumour-infiltrating lymphocytes assessment","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00395-5/fulltext","date":"2026-09-01","refs":["aphinity"]},{"feedId":"lancet-oncology","title":"[Comment] Afghan women's cancer crisis deserves its own response","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00343-8/fulltext","date":"2026-09-01","refs":[]},{"feedId":"lancet-oncology","title":"[Comment] Cancer care in Canada","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00352-9/fulltext","date":"2026-09-01","refs":[]},{"feedId":"lancet-oncology","title":"[Correspondence] Closing the gap in southeast Asia's diagnostic molecular oncology testing","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00376-1/fulltext","date":"2026-09-01","refs":["pathology-foundation-model"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2026; 27: 686–98","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00403-1/fulltext","date":"2026-09-01","refs":[]},{"feedId":"lancet-oncology","title":"[Perspectives] Rethinking failure and tolerance in oncology","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00398-0/fulltext","date":"2026-09-01","refs":[]},{"feedId":"lancet-oncology","title":"[Articles] Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00278-0/fulltext","date":"2026-09-01","refs":["tace","hcc","tremelimumab","lenvatinib","durvalumab","emerald-3","emerald"]},{"feedId":"lancet-oncology","title":"[Articles] Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00282-2/fulltext","date":"2026-09-01","refs":["nsclc","sclc","ivonescimab","egfr"]},{"feedId":"lancet-oncology","title":"[Articles] Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00283-4/fulltext","date":"2026-09-01","refs":["nsclc","sclc","alectinib","alina"]},{"feedId":"lancet-oncology","title":"[Articles] Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00175-0/fulltext","date":"2026-09-01","refs":["colorectal"]},{"feedId":"lancet-oncology","title":"[Articles] SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00238-X/fulltext","date":"2026-09-01","refs":["adc","nectin4"]},{"feedId":"lancet-oncology","title":"[Articles] High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00277-9/fulltext","date":"2026-09-01","refs":["androgen-deprivation","prostate"]},{"feedId":"lancet-oncology","title":"[Articles] Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0/fulltext","date":"2026-09-01","refs":["aphinity","her2"]},{"feedId":"lancet-oncology","title":"[Articles] Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6/fulltext","date":"2026-09-01","refs":["tnbc"]},{"feedId":"lancet-oncology","title":"[Review] Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00255-X/fulltext","date":"2026-09-01","refs":[]},{"feedId":"lancet-oncology","title":"[Personal View] Challenges in the use of the European Society for Radiotherapy and Oncology–European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00296-2/fulltext","date":"2026-09-01","refs":["ovarian"]},{"feedId":"jco","title":"Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02659","date":"2026-08-28","refs":["nct05318573","lung-cancer","durvalumab"]},{"feedId":"jco","title":"Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00355","date":"2026-08-27","refs":["nct06992258","colorectal","bevacizumab-glioma","bevacizumab","cetuximab","braf"]},{"feedId":"jco","title":"Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00161","date":"2026-08-27","refs":["lls-therapy-acceleration-program","leukaemia"]},{"feedId":"fda-oce","title":"FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma","date":"2026-08-26","refs":["revolution-medicines","daraxonrasib","beone"]},{"feedId":"fda-oce","title":"FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction","date":"2026-08-25","refs":["oesophageal-adenocarcinoma","jazz","beone","tislelizumab","zanidatamab","platinum-etoposide","nct06590246","gastric"]},{"feedId":"jco","title":"The Patient Who Could Not Die","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02505","date":"2026-08-25","refs":[]},{"feedId":"jco","title":"Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02234","date":"2026-08-25","refs":[]},{"feedId":"jco","title":"Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00640","date":"2026-08-25","refs":["nasopharyngeal","pucotenlimab","platinum-etoposide"]},{"feedId":"jco","title":"Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-03080","date":"2026-08-24","refs":["rhabdomyosarcoma","fdg-pet"]},{"feedId":"lancet-oncology","title":"[Comment] STAR-TREC and TESAR trials: strengthening the evidence for organ preservation in rectal cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00251-2/fulltext","date":"2026-08-23","refs":[]},{"feedId":"lancet-oncology","title":"[Articles] Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00228-7/fulltext","date":"2026-08-23","refs":[]},{"feedId":"jco","title":"Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02255","date":"2026-08-20","refs":["breast-her2-positive","breast-cancer","trastuzumab","nct06891833","pertuzumab","nct04514419","her2"]},{"feedId":"jco","title":"Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02604","date":"2026-08-17","refs":["litt","brain-tumours"]},{"feedId":"jco","title":"Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01931","date":"2026-08-14","refs":["nsclc","sclc","zipalertinib","lung-cancer"]},{"feedId":"jco","title":"Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02906","date":"2026-08-14","refs":["non-hodgkin-lymphoma","polatuzumab-vedotin","hodgkin-lymphoma","mosunetuzumab","obinutuzumab","nct07075328"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone","date":"2026-08-13","refs":["bms","multiple-myeloma","dexamethasone","daratumumab","iberdomide","proteasome"]},{"feedId":"lancet-oncology","title":"[News] New liver cancer medicine fast-tracked by UK Government","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00400-6/fulltext","date":"2026-08-13","refs":[]},{"feedId":"lancet-oncology","title":"[News] Saint Lucia launches national cancer registry","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00401-8/fulltext","date":"2026-08-13","refs":[]},{"feedId":"jco","title":"COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00528","date":"2026-08-12","refs":["spartalizumab","dabrafenib-trametinib","dabrafenib","trametinib","melanoma","nct06590246","braf"]},{"feedId":"jco","title":"Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-01846","date":"2026-08-12","refs":[]},{"feedId":"jco","title":"Forty","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00406","date":"2026-08-11","refs":[]},{"feedId":"jco","title":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00852","date":"2026-08-11","refs":["nct07412613","melanoma","nct05281471","nct06463665","nct06590246","nct07227870"]},{"feedId":"jco","title":"Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00671","date":"2026-08-11","refs":["trastuzumab-rezetecan","trastuzumab","nct06891833","nct05744687","nct06590246","nct07290088"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma","date":"2026-08-06","refs":["vusolimogene-oderparepvec","nivolumab","relatlimab-nivolumab","replimune","melanoma","nct06590246","pd1","beone"]},{"feedId":"jco","title":"Should Artificial Intelligence Direct Systemic Therapy Decisions in Pancreatic Cancer?","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00303","date":"2026-08-06","refs":[]},{"feedId":"jco","title":"Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00260","date":"2026-08-06","refs":["doxorubicin","dexrazoxane"]},{"feedId":"lancet-oncology","title":"[News] UK–Japan research collaboration for cancers in children and young people","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00392-X/fulltext","date":"2026-08-06","refs":[]},{"feedId":"lancet-oncology","title":"[News] 2030 hepatitis elimination targets might be missed in Europe","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00393-1/fulltext","date":"2026-08-06","refs":[]},{"feedId":"jco","title":"Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02508","date":"2026-08-03","refs":["prodige-24","nct05281471","nct06463665"]},{"feedId":"jco","title":"Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01665","date":"2026-08-03","refs":["nct05281471","nct06463665"]},{"feedId":"jco","title":"Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-03028","date":"2026-08-03","refs":["androgen-receptor","darolutamide","goserelin","nct05744687","nct07290088"]},{"feedId":"fda-oce","title":"FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy","date":"2026-07-31","refs":["androgen-receptor","prostate","pluvicto","novartis","psma"]},{"feedId":"jco","title":"Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02516","date":"2026-07-31","refs":["ewing-sarcoma"]},{"feedId":"lancet-oncology","title":"[News] Sweden plans to restrict PFAS","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00382-7/fulltext","date":"2026-07-30","refs":[]},{"feedId":"lancet-oncology","title":"[News] CARICOM moves towards regional framework for cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00383-9/fulltext","date":"2026-07-30","refs":[]},{"feedId":"jco","title":"Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-01471","date":"2026-07-29","refs":["tisagenlecleucel","nct05947851"]},{"feedId":"jco","title":"COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-03052","date":"2026-07-29","refs":["nct06992258","colorectal","atezolizumab","bevacizumab-glioma","bevacizumab","folfox"]},{"feedId":"jco","title":"Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-03009","date":"2026-07-29","refs":["colorectal"]},{"feedId":"lancet-oncology","title":"[Policy Review] Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00177-4/fulltext","date":"2026-07-29","refs":[]},{"feedId":"jco","title":"He Was Always There","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00540","date":"2026-07-28","refs":[]},{"feedId":"jco","title":"Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00327","date":"2026-07-27","refs":[]},{"feedId":"jco","title":"Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00243","date":"2026-07-24","refs":["adc","izalontamab-brengitecan","lung-cancer","mcla-129","nct07361003","nct05846867","nct07226986","nct06848699"]},{"feedId":"jco","title":"AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02979","date":"2026-07-24","refs":["cpx-351"]},{"feedId":"lancet-oncology","title":"[News] UK study to report cancer risk in armed services personnel","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00375-X/fulltext","date":"2026-07-23","refs":["alphabreak"]},{"feedId":"fda-oce","title":"FDA approves zidesamtinib for ROS1 -positive non-small cell lung cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer","date":"2026-07-22","refs":["nct05318573","zidesamtinib","lung-cancer","nuvalent","nct06590246","ros1","beone"]}]}